MannKind Corporation — Q1 2024 Form 10-Q Summary
Business context and reporting period
MannKind is a biopharmaceutical company commercializing Afrezza inhaled insulin and the V-Go wearable insulin-delivery device, while manufacturing Tyvaso DPI for United Therapeutics and receiving royalties on Tyvaso DPI sales. The company also develops inhaled therapies, including MNKD-101 and MNKD-201. This filing covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $66.3 million | $40.6 million | +63% |
| Commercial product sales | $18.8 million | $17.6 million | +7% |
| Collaboration and services revenue | $24.8 million | $11.4 million | +118% |
| Collaboration royalties | $22.7 million | $11.7 million | +94% |
| Operating income (loss) | $16.7 million | $(6.0) million | Improved |
| Net income (loss) | $10.6 million | $(9.8) million | Improved |
| Diluted EPS | $0.04 | $(0.04) | Improved |
| Net cash from operating activities | $6.7 million | $1.2 million | +$5.5 million |
- Commercial product gross profit was $14.9 million, compared with $12.0 million in the prior-year period; commercial product gross margin increased to 80% from 69%.
- Afrezza gross revenue increased 4%, while Afrezza net revenue increased 16% due primarily to higher pricing and lower estimated returns and other gross-to-net deductions.
- V-Go gross revenue decreased 12% and net revenue decreased 16%, primarily because of lower demand.
- Tyvaso DPI-related revenue from United Therapeutics, including manufacturing, services and royalties, totaled $47.5 million, compared with $23.0 million in Q1 2023.
- Research and development expense increased 79% to $10.0 million, primarily due to MNKD-101 development, the INHALE-3 Afrezza study and higher personnel costs.
- Selling expense declined 13% to $11.6 million, partly reflecting sales-force restructuring.
- Interest income increased to $3.4 million from $1.3 million, while Q1 2024 included $4.2 million of non-cash interest expense related to the sale of 1% of future Tyvaso DPI royalties.
Balance sheet, liquidity and debt
- Cash and cash equivalents were $193.3 million at March 31, 2024, compared with $238.5 million at December 31, 2023.
- Short-term investments were $107.5 million and long-term investments were $3.7 million. Cash, cash equivalents and investments totaled approximately $304.4 million.
- Total assets were $480.9 million, while total liabilities were $710.8 million and stockholders’ deficit was $230.0 million.
- Net cash decreased $45.2 million during the quarter, primarily because of a $68.4 million purchase of debt securities, $5.0 million of MidCap principal repayment and other financing uses.
- Debt carrying value was $264.1 million at quarter-end, consisting primarily of $227.2 million of senior convertible notes, $28.1 million of MidCap borrowings and an $8.8 million Mann Group convertible note.
- The senior convertible notes have $230.0 million principal outstanding, bear 2.5% interest and mature in March 2026; the initial conversion price is approximately $5.21 per share.
- The company stated that its liquidity resources are expected to fund operations for the next 12 months, although it has not generated operating income or positive operating cash flow consistently.
Material changes versus the prior comparable period
- Total revenue increased $25.6 million, driven primarily by higher Tyvaso DPI manufacturing activity and royalties, while commercial product revenue increased more modestly.
- The company shifted from a $6.0 million operating loss to $16.7 million of operating income and from a $9.8 million net loss to $10.6 million of net income.
- Operating cash generation improved from $1.2 million to $6.7 million.
- R&D investment increased substantially, reflecting expanded pipeline and post-marketing study activity.
- The company recorded a $1.2 million expense for estimated returns associated with V-Go sales predating its acquisition of the product; future returns are considered probable, but the filing does not provide a clear estimate of the remaining potential loss.
- During the quarter, the company issued 416,099 shares under its market-price stock purchase plan for $1.4 million and issued 15,285 shares to settle Mann Group note interest.
Guidance, outlook, risks and unusual items
- No formal revenue or earnings guidance is provided in the filing. Management expects continued spending on manufacturing, commercialization and development programs.
- In April 2024, the FDA cleared the MNKD-101 investigational new drug application and granted Fast Track designation, enabling a planned Phase 3 study for pulmonary nontuberculous mycobacterial disease. The FDA also cleared MNKD-201 to begin a Phase 1 study for pulmonary fibrotic diseases.
- On April 1, 2024, MannKind repaid and terminated the MidCap facility for approximately $31.6 million, including fees. A $3.3 million loss on extinguishment is expected in Q2 2024.
- On April 2, 2024, the company terminated the Mann Group convertible note by paying approximately $8.9 million and issuing 1.5 million shares. A $3.7 million extinguishment loss is expected in Q2 2024. Following these transactions, the senior convertible notes are the company’s only remaining notes outstanding.
- The company sold 1% of future Tyvaso DPI royalties for $150.0 million in December 2023, retaining a 9% royalty. It continues to recognize the full 10% royalty as revenue, but the sold portion is non-cash revenue and creates approximately 11.1% effective interest expense on the royalty liability.
- Material commitments include $58.9 million of remaining insulin purchase commitments and an estimated €9.5 million of future capacity fees under the Amphastar supply agreement. A recognized loss on purchase commitments of $62.7 million remained recorded at March 31, 2024.
- Key risks include dependence on United Therapeutics and Tyvaso DPI demand, manufacturing and supply-chain constraints, reliance on a limited insulin supplier, V-Go demand weakness, potential need for additional capital, the 2026 senior-notes maturity, clinical and regulatory uncertainty, payer coverage and reimbursement pressure, and foreign-exchange exposure.
- A 10% change in the U.S. dollar/euro exchange rate relative to March 31, 2024 would have affected pre-tax income by approximately $6.3 million.
- Management reported effective disclosure controls and procedures as of March 31, 2024 and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether Tyvaso DPI demand and United Therapeutics manufacturing volumes can sustain the sharp increase in royalty and collaboration revenue.
- The timing and funding plan for repayment, refinancing or conversion of the $230.0 million senior convertible notes due March 2026.
- Whether operating cash flow remains positive after excluding non-cash royalty revenue and other non-cash items.
- The commercial trajectory and gross-to-net assumptions for Afrezza and the continuing decline in V-Go demand.
- The scale, timing and clinical execution of MNKD-101 and MNKD-201 following the April 2024 regulatory clearances.
- The recoverability of inventory and the adequacy of reserves for insulin commitments, V-Go returns and other contingencies.
- The economic effect of the 1% royalty sale, including the non-cash revenue component, projected royalty remittances and approximately $148.0 million royalty liability at March 31, 2024.